He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of CME at Hematology division at Yale Cancer Center. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML). The focus clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches.